Weight-loss medications and their emerging effects on oral health
As prescriptions for weight-loss medications surge across Canada, oral health professionals are raising concerns about their potential impact in the dental chair. New findings suggest that drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro)—commonly used for diabetes and now approved for long-term weight management—can trigger several side effects that manifest in the oral cavity.
According to Statistics Canada, over 63% of Canadian adults were overweight or obese in 2018—a number that has likely increased—contributing to the popularity of these GLP-1 receptor agonists. While these drugs help lower blood sugar and reduce appetite, dental practitioners are beginning to observe side effects collectively termed as "Ozempic teeth."
Emerging oral health concerns with GLP-1 medications
Patients using these medications may experience:
- Dry mouth (xerostomia)
- Increased acid reflux
- Nausea or vomiting
- Altered taste (dysgeusia)
- Halitosis due to slowed digestion and reduced saliva
These symptoms can contribute to enamel erosion, dental caries, gingivitis, and heightened tooth sensitivity. Dentists are advised to monitor patients more closely and address these risks through preventive care and early intervention.
You may like: ‘Ozempic teeth’ linked to tooth decay and dental damage, experts warn
Preoperative concerns: anesthesia and delayed gastric emptying
Of greater clinical importance is the risk posed during dental procedures involving general anesthesia or deep sedation. GLP-1 drugs can significantly delay gastric emptying, increasing the risk of regurgitation and aspiration.
Guidelines suggest the following precautions:
- Daily GLP-1 dosing: Hold the drug on the day of the procedure
- Weekly GLP-1 dosing: Hold the drug one week prior to surgery (American Society of Anesthesiologists)
For weight-loss indications, some experts advise pausing semaglutide three weeks prior to procedures due to its extended half-life (Canadian Journal of Anesthesia)
Need for tailored dental care
Oral healthcare providers should consider modifying:
- Local anesthetic dosages
- Pain management plans
- Post-op care recommendations
Patients should be asked about their medication history—including GLP-1 drugs—during dental intake evaluations.
Awareness and safety first
As semaglutide and tirzepatide continue to be prescribed for weight loss and diabetes, dental teams must remain informed about their systemic and oral implications. Awareness, communication, and treatment modifications are key to ensuring patient safety and maintaining long-term oral health.
Stay informed. Stay ahead.
CLICK HERE TO FOLLOW Dental News Pakistan WhatsApp Channel for trusted oral care updates, expert insights, clinical research, policy news, and dental breakthroughs—delivered directly to you.